# Translational and Therapeutics Core

> **NIH NIH P30** · CLEVELAND CLINIC LERNER COM-CWRU · 2022 · $398,797

## Abstract

PROJECT SUMMARY
 The Translational Therapeutics Core (TTC) will provide the infrastructure and expertise necessary to
accelerate preclinical development of novel therapeutics for Alzheimer’s disease (AD) and AD-related
dementias (ADRD). The TTC will fill a critical void in the development of new therapeutics in the AD/ADRD
field by facilitating 2 critical components of translational science that are desperately under supported in
academia: (1) human target validation of basic science findings, and (2) network medicine approaches to
identify already existing agents for drug repurposing. A critical aspect of this is human data towards target
validation, through the realms of clinical experience, human genetics, and tissue expression. This is particularly
logistically challenging in the field of AD/ADRD due to scarcity of quality tissue and disease complexity.
Through the establishment of the Cleveland Alzheimer’s Disease Research Center (CADRC) Cores, the TTC
will work closely with the Biomarker Core (BC) to provide not only access to deeply phenotyped biological
samples, but expert guidance in the heterogeneity of ADRD. The TTC will bring to the CADRC a wealth of
shared resources including the Harrington Discovery Institute (HDI) at University Hospitals, which is part of the
Harrington Project for Discovery & Development, an international initiative designed to enable inventive
scientists to advance their discoveries into novel medicines that will improve human health by providing
funding and drug development support to bridge the gap between basic discovery and the clinical realm.
 The TTC is led by Dr. Andrew Pieper, Director of the Alzheimer’s Drug Discovery Foundation (ADDF) –
Harrington Scholar Program, which supports scientists to develop drugs that will prevent, treat, and cure
AD/ADRD. The TTC will identify and support researchers developing therapeutics currently targeted for
AD/ADRD locally in the CADRC, and nationally and internationally through Dr. Pieper’s relationship with ADDF
and HDI (Specific Aim 1). Researchers who have developed preclinical support for novel hypotheses related to
AD/ADRD will be supported through Dr. Cheng’s methods for network-based approaches to identify drugs that
might be repurposed for treating AD/ADRD. The TTC will also apply the same principles as in Specific Aim 1 to
support researchers developing novel therapeutics or hypotheses in other areas of medical research that might
also be applied to AD/ADRD, in order to support critical diversity of innovation for developing new treatments
for AD/ADRD (Specific Aim 2). In addition, coordination with the CADRC Biomarker Core (BC) will enable the
TTC to facilitate identification of markers related to new therapeutic approaches, which might be applied in
future clinical trials or patient care. By providing access and funds for target validation in human tissue using
the growing biospecimen collections in the CADRC Biomarker and Neuropathology Cores, the TTC will ...

## Key facts

- **NIH application ID:** 10474607
- **Project number:** 5P30AG072959-02
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** ANDREW A PIEPER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $398,797
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10474607

## Citation

> US National Institutes of Health, RePORTER application 10474607, Translational and Therapeutics Core (5P30AG072959-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10474607. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*